Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans

[1]  M. Joyner,et al.  Acute cyclooxygenase inhibition does not alter muscle sympathetic nerve activity or forearm vasodilator responsiveness in lean and obese adults , 2014, Physiological reports.

[2]  T. Golde,et al.  Complex Relationships between Substrate Sequence and Sensitivity to Alterations in γ-Secretase Processivity Induced by γ-Secretase Modulators , 2014, Biochemistry.

[3]  T. Golde,et al.  γ-Secretase Processing and Effects of γ-Secretase Inhibitors and Modulators on Long Aβ Peptides in Cells* , 2013, The Journal of Biological Chemistry.

[4]  T. Golde,et al.  γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.

[5]  D. Selkoe,et al.  Gamma-secretase as a target for Alzheimer's disease therapy: Small-molecule development , 2013, Alzheimer's & Dementia.

[6]  K. Bales,et al.  γ-Secretase Modulator (GSM) Photoaffinity Probes Reveal Distinct Allosteric Binding Sites on Presenilin* , 2013, The Journal of Biological Chemistry.

[7]  M. Takeda,et al.  γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. , 2013, Cell reports.

[8]  J. Dumin,et al.  Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models , 2013, Alzheimer's Research & Therapy.

[9]  R. Tanzi.  The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[10]  T. Schneider-Axmann,et al.  No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.

[11]  Martin Knapp,et al.  Donepezil and memantine for moderate-to-severe Alzheimer's disease. , 2012, The New England journal of medicine.

[12]  S. Weggen,et al.  Presenilin Is the Molecular Target of Acidic γ-Secretase Modulators in Living Cells , 2012, PloS one.

[13]  M. Wolfe.  γ-Secretase as a target for Alzheimer's disease. , 2012, Advances in pharmacology.

[14]  A. Iwai.  [Gamma-secretase inhibitors and modulators]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[15]  S. Weggen,et al.  Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer’s Disease , 2011, Current neuropharmacology.

[16]  T. Iwatsubo,et al.  Phenylpiperidine‐type γ‐secretase modulators target the transmembrane domain 1 of presenilin 1 , 2011, The EMBO journal.

[17]  K. Bales,et al.  Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. , 2011, ACS chemical neuroscience.

[18]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[19]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[20]  Daniel Oehlrich,et al.  γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. , 2011, Journal of medicinal chemistry.

[21]  Bryan Voss,et al.  Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[22]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[23]  J. Richardson,et al.  TASTPM Mice Expressing Amyloid Precursor Protein and Presenilin-1 Mutant Transgenes Are Sensitive to γ-Secretase Modulation and Amyloid-β42 Lowering by GSM-10h , 2010, Neurodegenerative Diseases.

[24]  S. C.A.,et al.  Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. , 2010 .

[25]  G. Cole,et al.  Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.

[26]  P. Zandi,et al.  Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. , 2010, CNS & neurological disorders drug targets.

[27]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[28]  B. Imbimbo.  An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease , 2009, Expert opinion on investigational drugs.

[29]  P. Pasqualetti,et al.  A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease , 2009, Aging clinical and experimental research.

[30]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[31]  J. Wiltfang,et al.  Independent Generation of Aβ42 and Aβ38 Peptide Species by γ-Secretase* , 2008, Journal of Biological Chemistry.

[32]  M. Wolfe,et al.  Substrate-targeting γ-secretase modulators , 2008, Nature.

[33]  P. Zandi,et al.  No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies , 2008, Neurology.

[34]  Donald R. Miller,et al.  Protective effects of NSAIDs on the development of Alzheimer disease , 2008, Neurology.

[35]  B. Jenkins,et al.  Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice , 2008, Brain Research.

[36]  Richard M. Page,et al.  Generation of Aβ38 and Aβ42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ-Secretase Modulation* , 2008, Journal of Biological Chemistry.

[37]  Richard M. Page,et al.  Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. , 2008, The Journal of biological chemistry.

[38]  E. Siemers,et al.  Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-&bgr; After Inhibition of &ggr;-Secretase , 2007 .

[39]  D. Galasko,et al.  Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals , 2007, Alzheimer disease and associated disorders.

[40]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[41]  J. Morris,et al.  Fluctuations of CSF amyloid-β levels , 2007, Neurology.

[42]  E. Siemers,et al.  Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. , 2007, Clinical neuropharmacology.

[43]  T. Golde,et al.  Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice , 2007, BMC Neuroscience.

[44]  T. Golde,et al.  Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. , 2006, The Journal of clinical investigation.

[45]  T. Golde,et al.  Anti-Aβ42– and anti-Aβ40–specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model , 2005 .

[46]  L. Thal,et al.  A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment , 2005, Neuropsychopharmacology.

[47]  C. Lines,et al.  Rofecoxib , 2004, Neurology.

[48]  L. Sansom,et al.  Stereoselective plasma protein binding of ibuprofen enantiomers , 2004, European Journal of Clinical Pharmacology.

[49]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[50]  S. Motzel,et al.  An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. , 2003, Contemporary topics in laboratory animal science.

[51]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[52]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.

[53]  D. Beher,et al.  Generation of C‐terminally truncated amyloid‐β peptides is dependent on γ‐secretase activity , 2002 .

[54]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[55]  D. Coppola,et al.  Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice , 2002, The Journal of Neuroscience.

[56]  D. Beher,et al.  Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. , 2002, Journal of neurochemistry.

[57]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[58]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[59]  Šimon Scharf,et al.  A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease , 1999, Neurology.

[60]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[62]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[63]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[64]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[65]  D. Jung,et al.  Dose-dependent pharmacokinetics of ibuprofen in the rat. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[66]  A. G. Zacchei,et al.  STUDIES ON THE ABSORPTION, DISTRIBUTION AND EXCRETION OF INDOMETHACIN IN VARIOUS SPECIES , 1966 .

[67]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .